Pharmacology, Toxicology and Pharmaceutical Science
Developmental Toxicity
100%
Androgen Receptor
100%
Gadolinium
100%
Embryotoxicity
75%
Biological Marker
70%
Contrast Medium
60%
Chronic Kidney Failure
54%
Ecosystem Toxicology
50%
Human Toxicology
50%
Applicability Domain
50%
Polychlorinated Biphenyl
50%
Oxybenzone
50%
Risk Evaluation
50%
Pazopanib
50%
Leukocyte Elastase Inhibitor
50%
Organic Compound
50%
Exemestane
50%
Leptin
50%
Chemicals and Drugs
50%
Adiponectin
50%
Heart Left Ventricle Hypertrophy
50%
Cannabinoid
50%
Adverse Event
50%
Epoxiconazole
50%
Transthyretin
50%
Thyroid Hormone
50%
Pyrethroid
50%
Breast Cancer
50%
Aromatase Inhibitor
50%
Estrogen Receptor
50%
Tetraxetan
50%
Gadoteric Acid
50%
Sivelestat
41%
Inflammation
40%
Cypermethrin
32%
Cardiovascular Disease
30%
Comorbidity
30%
Brain Natriuretic Peptide
26%
Sodium Valproate
25%
Toxicity Assessment
25%
Parathion Methyl
25%
Methyl Paraben
25%
Androgen Receptor Antagonist
25%
Polycyclic Aromatic Hydrocarbon
25%
1,1 Dichloro 2,2 Bis(4 Chlorophenyl)ethylene
25%
Adverse Outcome
25%
Prochloraz
25%
Retinoic Acid
25%
Endosulfan
25%
Ascorbic Acid
25%
Medicine and Dentistry
Breast Cancer
100%
In Vitro
81%
Cancer Therapy
75%
Cannabidiol
62%
Aromatase Inhibitor
62%
Androgen Receptor
62%
Estrogen Receptor
62%
Drug Mixture
50%
Biological Marker
50%
Left Ventricular Hypertrophy
50%
In Silico
50%
Cannabinoid
50%
Estrogen Receptor Positive Breast Cancer
50%
Aromatase
43%
Malignant Neoplasm
43%
Brain Natriuretic Peptide
43%
D-Dimer
33%
Diastolic Blood Pressure
33%
Public Health
25%
Risk Evaluation
25%
Organic Compound
25%
Inverse Agonist
25%
Chronic Kidney Disease
16%
Adipocytokine
16%
Tissue Plasminogen Activator
16%
Tissue Inhibitor of Metalloproteinase 1
16%
Multiple Linear Regression Analysis
16%
Leptin
16%
Exemestane
16%
Uric Acid
16%
Anastrozole
16%
Endothelial Function
16%
Cardiovascular System
16%
Iron Metabolism
16%
Cross Sectional Study
16%
Interleukin 6
16%
Amino Terminal Sequence
16%
Plasminogen Activator
16%
Kidney Fibrosis
16%
Fibrinolysis
16%
Standardized Patient
16%
Hemodialysis
16%
Cardiac Fibrosis
16%
Ultrafiltration
16%
End Stage Renal Disease
16%
Creatinine
16%
Breast Tumor
12%
Androgen Receptor Antagonist
12%
Diseases
12%
Cannabis
12%
Keyphrases
Metabolic Safety
50%
Human Neutrophil Elastase Inhibitors
50%
Sivelestat
50%
Exemestane
50%
Steroidal Aromatase Inhibitors
50%
Preanalytical Variables
50%
Left Ventricular Hypertrophy
50%
Mixture Risk Assessment
50%
Pazopanib
50%
Minor Cannabinoids
50%
Phytocannabinoids
50%
Biomarker 3
50%
Gadoteric Acid
50%
Chemical Mixtures
37%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
26%
Complex Mixtures
25%
Human Stem Cell Differentiation
25%
ER Antagonist
25%
Aging Kidney
25%
End-stage Renal Disease Patients
25%
Dialyzed Patients
25%
Chronic Hemodialysis
25%
Blood Ultrafiltration
25%
Hemogram
25%
Dialysis Efficiency
25%
Ultrafiltration Volume
25%
Driver Factors
25%
Hemodialysis Membrane
20%
Caki-1 Cells
18%
Anastrozole
16%
Multitarget Drugs
16%
Erythropoiesis
16%
Thyroid-disrupting Effect
14%
Urinary 3-phenoxybenzoic Acid
14%
Glycerophospholipid Metabolism
12%
Childrens
12%
Fetus
12%
Component-based
12%
Effect Analysis
12%
Web-based
12%
European Green Deal
12%
Risk Estimation
12%
Green Deal
12%
Organic Chemicals
12%
High-throughput
12%
Regulatory Measures
12%
PAH Metabolites
12%
Risk Calculation
12%
Exposure Data
12%
Blood Levels
12%
